Birdwood Therapeutics

Molecular Design for any target, mechanism, and modality.

United States · Founded 2024

Employees
1–10
Founded
2024
Business Model
B2B
Last Round
SeedOct 2025
Rounds
1

About

Birdwood Therapeutics is a biotechnology company building AI foundation models for molecular design, trained on high-throughput kinetic measurements across up to one million binders simultaneously. Its proprietary discovery platform combines DNA-encoded scaffolds for programmable molecular diversity with biophysical AI models that learn the physics of molecular recognition, enabling predictive design of small molecules, peptides, and oligonucleotides. The company applies this platform to binder discovery, kinetic profiling, and next-generation induced proximity medicines including degraders, stabilizers, and activators.

Summary

Birdwood Therapeutics is an Artificial Intelligence company based in United States, founded in 2024. Its most recent funding was a Seed round in Oct 2025. Investors include Fifty Years.

Sign up to view the funding chart

Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.

Funding History

SeedSeed RoundOct 2025

Investors

Similar Companies